BR0213162A - Methods for the prevention and treatment of bone loss with steroid compounds. - Google Patents
Methods for the prevention and treatment of bone loss with steroid compounds.Info
- Publication number
- BR0213162A BR0213162A BR0213162-5A BR0213162A BR0213162A BR 0213162 A BR0213162 A BR 0213162A BR 0213162 A BR0213162 A BR 0213162A BR 0213162 A BR0213162 A BR 0213162A
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- methods
- bone loss
- steroid compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS PARA PREVENçãO E TRATAMENTO DA PERDA óSSEA COM COMPOSTOS ESTERóIDES". A presente invenção refere-se a um método de prevenção e tratamento de distúrbios anormais metabólicos ósseos em uma mulher em atividade de pós-menopausa ou ovariectomizada, o qual compreende a administração à dita mulher de uma quantidade terapeuticamente eficaz de exemestano ou 17-hidro-exemestano, individualmente ou em combinação com agentes terapêuticos adicionais."METHODS FOR PREVENTION AND TREATMENT OF BONE LOSS WITH STEROID COMPOUNDS". The present invention relates to a method of preventing and treating abnormal bone metabolic disorders in a postmenopausal or ovariectomized woman, which comprises administering to said woman a therapeutically effective amount of exemestane or 17-hydroxydehyde. individually, or in combination with additional therapeutic agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32820901P | 2001-10-10 | 2001-10-10 | |
PCT/EP2002/011123 WO2003032961A2 (en) | 2001-10-10 | 2002-09-30 | Methods for preventing and treating bone loss with steroid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213162A true BR0213162A (en) | 2004-09-14 |
Family
ID=23279989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213162-5A BR0213162A (en) | 2001-10-10 | 2002-09-30 | Methods for the prevention and treatment of bone loss with steroid compounds. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1435967A2 (en) |
JP (1) | JP2005508958A (en) |
KR (1) | KR20050032507A (en) |
CN (1) | CN1713915A (en) |
BR (1) | BR0213162A (en) |
CA (1) | CA2463142A1 (en) |
IL (1) | IL161162A0 (en) |
MX (1) | MXPA04003405A (en) |
NZ (1) | NZ532064A (en) |
PL (1) | PL370080A1 (en) |
WO (1) | WO2003032961A2 (en) |
ZA (1) | ZA200402734B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
WO2005027916A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors |
AU2004203436A1 (en) | 2003-09-24 | 2005-04-14 | Bioxell Spa | Compound and use in treatment |
EP1937251A2 (en) * | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
MX2012014431A (en) | 2010-06-10 | 2013-02-26 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof. |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
EP4249471A3 (en) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
AU2016381336A1 (en) | 2015-12-30 | 2018-06-28 | Saint Louis University | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8721384D0 (en) * | 1987-09-11 | 1987-10-21 | Erba Farmitalia | 17-substituted andro-sta-1 4-dien-3-one derivatives |
GB2294879A (en) * | 1994-10-19 | 1996-05-15 | Merck & Co Inc | Cylcooxygenase-2 Inhibitors |
US6590079B2 (en) * | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
ID28460A (en) * | 1998-07-08 | 2001-05-24 | Lipogenics Inc | COMPOSITION AND METHODS FOR TREATMENT AND PREVENTION OF BONE DISEASE USING TOCOTRIENOL |
WO2001012206A2 (en) * | 1999-08-13 | 2001-02-22 | Heinrich Wieland | Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
-
2002
- 2002-09-30 CA CA002463142A patent/CA2463142A1/en not_active Abandoned
- 2002-09-30 KR KR1020047005231A patent/KR20050032507A/en not_active Application Discontinuation
- 2002-09-30 WO PCT/EP2002/011123 patent/WO2003032961A2/en not_active Application Discontinuation
- 2002-09-30 EP EP02801313A patent/EP1435967A2/en not_active Withdrawn
- 2002-09-30 IL IL16116202A patent/IL161162A0/en unknown
- 2002-09-30 PL PL02370080A patent/PL370080A1/en not_active Application Discontinuation
- 2002-09-30 MX MXPA04003405A patent/MXPA04003405A/en unknown
- 2002-09-30 BR BR0213162-5A patent/BR0213162A/en not_active IP Right Cessation
- 2002-09-30 JP JP2003535765A patent/JP2005508958A/en active Pending
- 2002-09-30 NZ NZ532064A patent/NZ532064A/en unknown
- 2002-09-30 CN CNA028201167A patent/CN1713915A/en active Pending
-
2004
- 2004-04-07 ZA ZA200402734A patent/ZA200402734B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2463142A1 (en) | 2003-04-24 |
PL370080A1 (en) | 2005-05-16 |
EP1435967A2 (en) | 2004-07-14 |
WO2003032961A3 (en) | 2003-09-04 |
IL161162A0 (en) | 2004-08-31 |
KR20050032507A (en) | 2005-04-07 |
JP2005508958A (en) | 2005-04-07 |
CN1713915A (en) | 2005-12-28 |
MXPA04003405A (en) | 2004-06-18 |
NZ532064A (en) | 2006-04-28 |
WO2003032961A2 (en) | 2003-04-24 |
ZA200402734B (en) | 2005-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9813524A (en) | Processes for treating toxicities associated with administering a therapeutic agent to a mammal, for treating toxicities associated with a mammal's exposure to radiation therapy, for treating neuro- or nephrodisturbs in a human, and for treating disorders and clinical symptoms associated with type i or type ii diabetes in a human | |
BR0013122A (en) | Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions | |
BR0211364A (en) | Pharmaceutical composition for treating diseases associated with reduction in bone mass comprising ep4 agonist as active component | |
BR0009647A (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers | |
BR0318269A (en) | compositions, targets, methods and devices for the therapy of ocular and periocular disorders | |
BR0211062A (en) | Combinations for the treatment of inflammatory disorders | |
BR9712824A (en) | Ophthalmic composition of neurotrophic factor, treatment agent for functional optic nerve disorder and method for treating functional optic nerve disorder | |
BR0206639A (en) | Sterol Absorption Inhibitor (s) Combinations With Blood Modifier (s) For Treatment Of Vascular Conditions | |
BR9812134A (en) | Pharmaceutical composition for the treatment of dysmenorrhea and premature birth | |
BRPI0417006A (en) | local intraosseous administration of bone forming agents and anti-resorptive agents and devices therefor | |
BR0317747A (en) | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment | |
BR0015974A (en) | Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound | |
BRPI0510761A (en) | methods of treating a patient afflicted with at least one condition and reducing or eliminating wrinkles | |
GB0108592D0 (en) | Therapeutic agents | |
BRPI0512220A (en) | method for treating, preventing or ameliorating a disease or disorder; pharmaceutical composition; process for the preparation of a compound; and use of a compound | |
BR0309623A (en) | Regulating Agents. inhibit or modulate connective tissue growth factor (ctgf) activity and / or expression as a sole means of decreasing intraocular pressure and treating glaucomatous retinopathies / optic neuropathies | |
BR0113447A (en) | Method of treating or preventing cancer in a human, and, pharmaceutical composition | |
MXPA03010843A (en) | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease. | |
BRPI0411295A (en) | compounds and their use in therapy | |
BR0014312A (en) | Combination of loteprednol and antihistamines | |
BR9914419A (en) | Perception improvement therapy | |
BRPI0412919A (en) | combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders | |
BR0315573A (en) | Method for treating, preventing, controlling and / or modifying pain in a patient and pharmaceutical composition. | |
BR0200246A (en) | Combination treatment for depression | |
BRPI0408491A (en) | treatment of alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |